王 佳,洪忠新,武 力,丁冰杰,顧中一,葛智文,柳 露,畢研霞,李 偉
100050 北京市,首都醫(yī)科大學(xué)附屬北京友誼醫(yī)院營養(yǎng)科
· 論著·
·專題研究·
改善膳食模式對北京市房山區(qū)張坊村中老年高血壓患者炎性指標(biāo)的影響
王 佳,洪忠新*,武 力,丁冰杰,顧中一,葛智文,柳 露,畢研霞,李 偉
100050 北京市,首都醫(yī)科大學(xué)附屬北京友誼醫(yī)院營養(yǎng)科
目的 通過補(bǔ)充抗動(dòng)脈粥樣硬化食療粉,改善北京市房山區(qū)張坊村超重或肥胖高血壓患者的膳食模式,觀察其對患者炎性指標(biāo)水平的影響。方法 2015-06-27至2015-10-11,從北京市房山區(qū)張坊村245例中老年(45~75歲)村民數(shù)據(jù)庫中,選取符合納入標(biāo)準(zhǔn)的超重或肥胖的1級高血壓患者30例為研究對象。采用隨機(jī)數(shù)字法將患者分為一組和二組,各15例。進(jìn)行交叉干預(yù)研究,最終有24例患者(一組11例,二組13例)完成試驗(yàn)。分別于試驗(yàn)前(T0)、6周末(T1)及14周末(T2)測量患者炎性指標(biāo)〔核因子κB(NF-κB)、可溶性細(xì)胞間黏附分子1(sICAM-1)、可溶性血管間黏附分子1(sVCAM-1)、E-選擇素(E-Selectin)、整合素(Integrin)、脂聯(lián)素(Adiponectin)、超敏C反應(yīng)蛋白(hs-CRP)、空腹血糖(FBG)、空腹胰島素(FIN)、穩(wěn)態(tài)模型胰島素抵抗指數(shù)(HOMA-IR)〕。結(jié)果 一組T1時(shí)sICAM-1高于T2時(shí),T0時(shí)NF-κB、Integrin高于T2時(shí)(P<0.05)。二組T1時(shí)sICAM-1高于T2時(shí),T0時(shí)sICAM-1、sVCAM-1高于T2時(shí)(P<0.05)。T0、T1、T2時(shí),兩組NF-κB、sICAM-1、sVCAM-1、E-Selectin、Integrin、Adiponectin、hs-CRP、HOMA-IR比較,差異均無統(tǒng)計(jì)學(xué)意義(P>0.05)。結(jié)論 對于超重或肥胖的高血壓患者,控制總能量攝入量,同時(shí)增加抗動(dòng)脈粥樣硬化食療粉,改善膳食模式,可以降低炎性指標(biāo)的水平,并可持續(xù)發(fā)揮作用,從而具有一定降低血壓效果。
高血壓;飲食習(xí)慣;炎癥
王佳,洪忠新,武力,等.改善膳食模式對北京市房山區(qū)張坊村中老年高血壓患者炎性指標(biāo)的影響[J].中國全科醫(yī)學(xué),2017,20(3):299-303.[www.chinagp.net]
WANG J,HONG Z X,WU L,et al.Effects of dietary pattern improvement on the levels of inflammatory markers in middle-aged and older people with hypertension in Zhangfang Village of Fangshan District of Beijing[J].Chinese General Practice,2017,20(3):299-303.
中國高血壓發(fā)病率逐年增加[1-3],且農(nóng)村發(fā)病率高于城市[4]。本研究組前期對北京市房山區(qū)張坊村研究發(fā)現(xiàn),該村中老年人高血壓患病率高達(dá)59.1%[5]。且研究還發(fā)現(xiàn),該人群中精白米面加腌菜的膳食模式與高血壓患病率密切相關(guān),同時(shí),這種高碳水化合物攝入的膳食模式可能會(huì)引起炎性反應(yīng),從而對血壓產(chǎn)生影響[6]。國外研究也發(fā)現(xiàn),低碳水化合物飲食相比低脂飲食更能降低血漿炎性指標(biāo)水平[7];且炎性指標(biāo)水平與高血壓密切相關(guān)[8]。本研究旨在通過補(bǔ)充抗動(dòng)脈粥樣硬化食療粉,改良張坊村居民以精白米面為主的膳食模式,觀察其對張坊村中老年高血壓患者炎性指標(biāo)水平的影響,提出可以降低我國農(nóng)村地區(qū)高血壓患病率的可行性膳食干預(yù)模式。
1.1 研究對象 2015-06-27至2015-10-11,從北京市房山區(qū)張坊村245例中老年(45~75歲)村民數(shù)據(jù)庫[5,8]中,選取符合納入標(biāo)準(zhǔn)[9]的超重或肥胖的1級高血壓患者30例為研究對象。采用隨機(jī)數(shù)字表法將患者分為一組和二組,各15例。
1.2 研究方法 本研究為隨機(jī)交叉對照試驗(yàn)。第一階段:一組補(bǔ)充抗動(dòng)脈粥樣硬化食療粉,二組保持原膳食模式,共6周;第二階段:為2周的洗脫期,一組恢復(fù)原膳食模式,二組仍保持原膳食模式;第三階段:第9周開始二組補(bǔ)充抗動(dòng)脈粥樣硬化食療粉,一組保持原膳食模式,共6周。最終有24例患者(一組11例,二組13例)完成試驗(yàn)。分別于試驗(yàn)前(T0)、6周末(T1)及14周末(T2),測量患者炎性指標(biāo)﹝核因子κB(NF-κB)、可溶性細(xì)胞間黏附分子1(sICAM-1)、可溶性血管間黏附分子1(sVCAM-1)、E-選擇素(E-Selectin)、整合素(Integrin)、脂聯(lián)素(Adiponectin)、超敏C反應(yīng)蛋白(hs-CRP)、空腹血糖(FBG)、空腹胰島素(FIN)、穩(wěn)態(tài)模型胰島素抵抗指數(shù)(HOMA-IR)﹞。其中NF-κB、sICAM-1、sVCAM-1、E-Selectin、Integrin、Adiponectin采用ELISA法測定,hs-CRP采用免疫比濁法,F(xiàn)BG采用氧化酶法測定,F(xiàn)IN采用化學(xué)發(fā)光法測定,HOMA-IR=(FBG×FIN)/22.5。
2.1 組內(nèi)比較 一組T0時(shí)NF-κB、sICAM-1、sVCAM-1、E-Selectin、Integrin、Adiponectin、hs-CRP、HOMA-IR與T1時(shí)比較,T1時(shí)NF-κB、sVCAM-1、E-Selectin、Integrin、Adiponectin、hs-CRP、HOMA-IR與T2時(shí)比較,T0時(shí)sICAM-1、sVCAM-1、E-Selectin、Adiponectin、hs-CRP、HOMA-IR與T2時(shí)比較,差異均無統(tǒng)計(jì)學(xué)意義(P>0.05);一組T1時(shí)sICAM-1高于T2時(shí),T0時(shí)NF-κB、Integrin高于T2時(shí),差異均有統(tǒng)計(jì)學(xué)意義(P<0.05)。二組T0時(shí)NF-κB、sICAM-1、sVCAM-1、E-Selectin、Integrin、Adiponectin、hs-CRP、HOMA-IR與T1時(shí)比較,T1時(shí)NF-κB、sVCAM-1、E-Selectin、Integrin、Adiponectin、hs-CRP、HOMA-IR與T2時(shí)比較,T0時(shí)NF-κB、E-Selectin、Integrin、Adiponectin、hs-CRP、HOMA-IR與T2時(shí)比較,差異均無統(tǒng)計(jì)學(xué)意義(P>0.05);二組T1時(shí)sICAM-1高于T2時(shí),T0時(shí)sICAM-1、sVCAM-1高于T2時(shí),差異均有統(tǒng)計(jì)學(xué)意義(P<0.05,見表1)。2.2 組間比較T0、T1、T2時(shí),兩組NF-κB、sICAM-1、sVCAM-1、E-Selectin、Integrin、Adiponectin、hs-CRP、HOMA-IR比較,差異均無統(tǒng)計(jì)學(xué)意義(P>0.05,見表1)。
我國高血壓患病率逐年增高,且有北方高于南方、農(nóng)村高于城市的趨勢[1-4]。本研究組前期研究發(fā)現(xiàn),補(bǔ)充抗動(dòng)脈粥樣硬化食療粉后,當(dāng)能量適度增加且膳食結(jié)構(gòu)改善時(shí),收縮壓和舒張壓均有下降趨勢;當(dāng)能量顯著增加且膳食結(jié)構(gòu)未改善時(shí),收縮壓有上升趨勢,舒張壓未改變;而在能量下降而膳食結(jié)構(gòu)不改善時(shí),血壓仍有上升趨勢[9]。本研究在前期研究基礎(chǔ)上,觀察抗動(dòng)脈粥樣硬化食療粉對張坊村中老年高血壓患者炎性指標(biāo)水平的影響。
表1 兩組患者不同時(shí)間炎性指標(biāo)比較±s)
注:a表示T0時(shí)與T1時(shí)比較,b表示T1時(shí)與T2時(shí)比較,c表示T0時(shí)與T2時(shí)比較;NF-κB=核因子κB,sICAM-1=可溶性細(xì)胞間黏附分子1,sVCAM-1=可溶性血管間黏附分子1,E-Selectin=E-選擇素,Integrin=整合素,Adiponectin=脂聯(lián)素,hs-CRP=超敏C反應(yīng)蛋白,HOMA-IR=穩(wěn)態(tài)模型胰島素抵抗指數(shù),-為無此項(xiàng)
3.1 營養(yǎng)素?cái)z入量與炎性指標(biāo)的關(guān)系 sICAM-1是評價(jià)血管炎性反應(yīng)的標(biāo)準(zhǔn),血液循環(huán)中炎性反應(yīng)水平能反映內(nèi)皮細(xì)胞的活化及動(dòng)脈粥樣硬化的程度。營養(yǎng)不合理與sICAM-1密切相關(guān)。WITKOWSKA[10]對22例絕經(jīng)后的肥胖婦女研究發(fā)現(xiàn),當(dāng)采取標(biāo)準(zhǔn)能量(平均2 238 kcal/d)的低脂高碳水化合物的飲食攝入時(shí),體質(zhì)量無變化,但對炎性指標(biāo)卻有不利影響,如Adiponectin下降;當(dāng)采取限制能量(平均1 200 kcal/d)的低脂高碳水化合物的飲食攝入時(shí),體質(zhì)量降低6 kg,hs-CRP下降、Adiponectin升高。說明對肥胖者采取限制能量的低脂高碳水化合物的飲食時(shí),隨著體質(zhì)量降低,機(jī)體炎性反應(yīng)水平亦下降。筆者前期研究也發(fā)現(xiàn),蛋白質(zhì)和脂肪的攝入量與sICAM-1呈負(fù)相關(guān),碳水化合物攝入量與sICAM-1呈正相關(guān)[6],且可以通過改善膳食模式來降低炎性因子水平。FORSYTHE等[7]比較了限制能量攝入量的低脂高碳水化合物飲食(LED,能量攝入量1 478 kcal;碳水化合物56%,脂肪24%,蛋白質(zhì)20%)與限制能量攝入量的極低碳水化合物飲食(VLCKD,能量攝入量1 504 kcal;碳水化合物12%,脂肪59%,蛋白質(zhì)28%)對代謝綜合征患者的效果(共3個(gè)月),結(jié)果發(fā)現(xiàn),VLCKD雖增加血漿花生四烯酸的水平,但血漿炎性指標(biāo)的變化反而更好,sICAM-1下降更明顯。BALLARD等[11]關(guān)于VLCKD對口服他汀類藥物患者影響的研究發(fā)現(xiàn),VLCKD有類似于他汀類藥物的作用,可改善脂質(zhì)代謝、炎癥及血管內(nèi)皮功能等;從第3周開始,sICAM-1便顯著下降。其可能的原因是:VLCKD增加酮體的生成,抑制機(jī)體的氧化應(yīng)激,降低sICAM-1,進(jìn)而改善血管的內(nèi)皮功能。ZOU等[12]研究發(fā)現(xiàn),單純限制總能量攝入量可阻礙氧化應(yīng)激和可溶性黏附分子的生成。MEDINA-REMON等[13]研究發(fā)現(xiàn),補(bǔ)充堅(jiān)果可以增加多酚的攝入量,補(bǔ)充多酚可以顯著降低血漿炎性指標(biāo),如VCAM-1、ICAM-1、白介素6(IL-6)、腫瘤壞死因子α(TNF-α),且收縮壓和舒張壓與炎性指標(biāo)下降呈平衡下降趨勢。
NF-κB及其調(diào)節(jié)的近100個(gè)基因編碼產(chǎn)生的蛋白質(zhì)如黏附分子、Integrin、E-Selectin等,參與血管炎性反應(yīng),引起血管內(nèi)皮功能紊亂。不良的膳食模式,如飽和脂肪酸、反式脂肪酸、過量能量攝入量等,均可激活NF-κB,進(jìn)而引起黏附分子的增加;而α-亞麻酸、不飽和脂肪酸、硒及可溶性纖維素等可抑制NF-κB。通常情況下,血管內(nèi)皮細(xì)胞內(nèi)NF-κB先被活化,黏附分子增加,進(jìn)一步激活單核巨噬細(xì)胞內(nèi)NF-κB,黏附分子進(jìn)一步增加[14]。
Adiponectin作為一種胰島素超敏化激素,可以增加促進(jìn)骨骼肌細(xì)胞的脂肪酸氧化和糖吸收,明顯增強(qiáng)胰島素的抑制糖異生作用,抑制肝臟的糖生成,是機(jī)體的脂質(zhì)代謝和血糖穩(wěn)態(tài)的調(diào)控網(wǎng)絡(luò)中的重要調(diào)節(jié)因子。血漿中Adiponectin與三酰甘油和低密度脂蛋白呈負(fù)相關(guān),與高密度脂蛋白呈正相關(guān)。OUCHI等[15]、SHIBATA等[16]發(fā)現(xiàn),Adiponectin可以降低單核細(xì)胞的黏附作用,還可以降低多種黏附分子(VCAM-1、ICAM-1、E-Selectin)在內(nèi)皮細(xì)胞的表達(dá)。NF-κB是參與由TNF-α刺激VCAM-1、ICAM-1、E-Selectin轉(zhuǎn)錄調(diào)節(jié)的重要因子。Adiponectin可能通過抑制NF-κB信號通路調(diào)節(jié)內(nèi)皮細(xì)胞的功能。Adiponectin特異性地抑制TNF-α誘導(dǎo)NF-κB信號通路的激活。
補(bǔ)充抗動(dòng)脈粥樣硬化食療粉可以增加膳食中蛋白質(zhì)、膳食纖維、不飽和脂肪酸等營養(yǎng)成分的攝入量[9],研究發(fā)現(xiàn),膳食纖維、不飽和脂肪酸均具有抑制NF-κB被激活的作用[14]。本研究結(jié)果顯示,一組T0時(shí)sICAM-1低于T1時(shí),NF-κB、sVCAM-1高于T1時(shí),但均無統(tǒng)計(jì)學(xué)差異,其原因可能是,雖然一組補(bǔ)充食療粉后膳食模式改善,但總能量攝入量升高[9]。一組T1時(shí)NF-κB、sVCAM-1高于T2時(shí),但無統(tǒng)計(jì)學(xué)差異;一組T1時(shí)sICAM-1高于T2時(shí);說明抗動(dòng)脈粥樣硬化食療粉具有明顯的后遺效應(yīng),這與本研究組測定的是單核-巨噬細(xì)胞的NF-κB有關(guān),也與干預(yù)時(shí)間較短有關(guān),也可能與代謝通路中復(fù)雜的蛋白質(zhì)組分的t1/2不等有關(guān)。二組T0時(shí)NF-κB、sICAM-1、sVCAM-1、E-Selectin、Integrin、Adiponectin、hs-CRP、HOMA-IR高于T1時(shí),但無統(tǒng)計(jì)學(xué)差異,與WITKOWSKA[10]研究結(jié)果相同。二組T1時(shí)NF-κB高于T2時(shí),sVCAM-1高于T2時(shí),但無統(tǒng)計(jì)學(xué)差異;二組T1時(shí)sICAM-1高于T2時(shí),說明內(nèi)皮細(xì)胞內(nèi)NF-κB先被抑制,黏附分子降低,進(jìn)一步抑制單核巨噬細(xì)胞內(nèi)NF-κB,黏附分子進(jìn)一步下降[14]。
3.2 營養(yǎng)素?cái)z入量、炎性指標(biāo)與血壓的關(guān)系 一組干預(yù)階段,膳食模式改善,但總能量攝入量仍超標(biāo)[9],導(dǎo)致炎性指標(biāo)未明顯下降,炎性指標(biāo)下降有降低血壓的作用,但被總能量攝入量超標(biāo)其升高血壓的作用趨所掩蓋,因此血壓沒有顯著降低[9]。
一組對照階段,總能量攝入量仍超標(biāo),膳食模式未改善[9];sICAM-1下降;余炎性指標(biāo)均下降,但無統(tǒng)計(jì)學(xué)差異。分析原因可能由于抗動(dòng)脈粥樣硬化食療粉后對于炎性指標(biāo)具有一定的后遺效應(yīng),對照階段炎性指標(biāo)繼續(xù)下降,但炎性指標(biāo)降低血壓的程度被因飲食不合理致升高血壓的程度所掩蓋,最終還是引起血壓升高[9]。
二組對照階段,總能量攝入量下降,但膳食模式未改善[9];炎性指標(biāo)均下降,但無統(tǒng)計(jì)學(xué)差異?;颊咴诖穗A段由于蛋白質(zhì)、脂肪、膳食纖維等有益血壓下降的營養(yǎng)素?cái)z入量下降,此時(shí)只是總能量攝入量下降,但血壓仍有上升趨勢[9],可能與一氧化氮(NO)依賴的舒血管機(jī)制以及血流依賴的舒血管機(jī)制相關(guān)。
二組干預(yù)階段,總能量攝入量增加,但膳食模式未改善[9];sICAM-1下降;sVCAM-1、NF-κB下降,但無統(tǒng)計(jì)學(xué)差異??偰芰繑z入量超標(biāo)引起血壓升高的程度掩蓋了炎性指標(biāo)降低血壓的程度,最終還是引起血壓升高[9]。
綜上所述,對于超重或肥胖的高血壓患者,控制總能量攝入量,同時(shí)增加抗動(dòng)脈粥樣硬化食療粉,改善膳食模式,可以降低炎性指標(biāo)的水平,并可持續(xù)發(fā)揮作用,具有一定降低血壓效果。這種飲食可能還通過NO依賴的舒血管機(jī)制以及血流依賴的舒血管機(jī)制影響血壓,有待于進(jìn)一步研究。
作者貢獻(xiàn):王佳進(jìn)行試驗(yàn)設(shè)計(jì)、實(shí)施、資料整理、撰寫論文;武力、丁冰杰、顧中一、葛智文、柳露、畢研霞、李偉進(jìn)行試驗(yàn)實(shí)施和資料收集;洪忠新進(jìn)行試驗(yàn)設(shè)計(jì)、對文章負(fù)責(zé),進(jìn)行質(zhì)量控制及審校。
本文無利益沖突。
[1]TAO S,WU X,DUAN X,et al.Hypertension prevalence and status of awareness,treatment and control in China[J].Chin Med J(Engl),1995,108(7):483-489.
[2]WU Y,HUXLEY R,LI L,et al.Prevalence,awareness,treatment,and control of hypertension in China:data from the China National Nutrition and Health Survey 2002[J].Circulation,2008,118(25):2679-2686.
[3]WANG J,ZHANG L,WANG F,et al.Prevalence,awareness,treatment,and control of Hypertension in China:results from a national survey[J].Am J Hypertens,2014,27(11):1355-1361.
[4]郭杰,余燦清,呂筠,等.中國10個(gè)地區(qū)人群高血壓患病率、知曉率、治療率和控制情況分析[J].中華流行病學(xué)雜志,2016,37(4):469-474. GUO J,YU C Q,LYU Y,et al.Status of prevalence,awareness,treatment and controll on hypertension among adults in 10 regions,China[J].Chinese Journal of Epidemiology,2016,37(4):469-474.
[5]王佳,洪忠新,武力,等.北京市房山區(qū)張坊村中老年人原發(fā)性高血壓病危險(xiǎn)因素研究[J].中國全科醫(yī)學(xué),2013,16(28):3341-3345. WANG J,HONG Z X,WU L,et al.Risk factors of primary hypertension for middle aged and elderly people in Zhangfang Village of Fangshan District in Beijing[J].Chinese General Practice,2013,16(28):3341-3345.
[6]王佳,洪忠新,武力,等.中老年人膳食模式與高血壓發(fā)病機(jī)制探討[J].中國全科醫(yī)學(xué),2016,19(14):1706-1710. WANG J,HONG Z X,WU L,et al.Dietary pattern and pathogenesis of hypertension of middle aged and elderly people[J].Chinese General Practice,2016,19(14):1706-1710.
[7]FORSYTHE C E,PHINNEY S D,FERNANDEZ M L,et al.Comparison of low fat and low carbohydrate diets on circulating fatty acid composition and markers of inflammation[J].Lipids,2008,43(1):65-77.
[8]MITU F,REZUS E,BANU C,et al.Inflammatory markers in hypertensive patients and influence of some associated metabolic risk factor[J].Rev Med Chir Soc Med Nat Iasi,2014,118(3):631-636.
[9]王佳,洪忠新,武力,等.改善膳食模式對北京市房山區(qū)張坊村中老年超重或肥胖高血壓患者血壓和人體成分及血脂譜的影響研究[J].中國全科醫(yī)學(xué),2017,20(3):290-298. WANG J,HONG Z X,WU L,et al.Effects of dietary pattern improvement on blood pressure,body composition and blood lipid profile of overweight or obese middle-aged and aged people with hypertension in Zhangfang Village of Fangshan District of Beijing[J].Chinese General Practice,2017,20(3):290-298.
[10]WITKOWSKA A M.Soluble ICAM-1:a marker of vascular inflammation and lifestyle[J].Cytokine,2005,31(2):127-134.
[11]BALLARD K D,QUANN E E,KUPCHAK B R,et al.Dietary carbohydrate restriction improves insulin sensitivity,blood pressure,microvascular function,and cellular adhesion markers in individuals taking statins[J].Nutr Res,2013,33(11):905-912.
[12]ZOU Y,JUNG K J,KIM J W,et al.Alteration of soluble adhesion molecules during aging and their modulation by calorie restriction[J].FASEB J,2004,18(2):320-322.
[13]MEDINA-REMON A,CASAS R,TRESSSERRA-RIMBAU A,et al.Polyphenol intake from a Mediterranean diet decreases inflammatory bilmarkers related to atherosclerosis:a substudy of the PREDIMED trial[J].Br J Clin Pharmacol,2017,83(1):114-128.
[14]PHAM T X,LEE J Y.Anti-inflammatory effect of spirulina platensis in Macrophages is beneficial for adipocyte differentiation and maturation by inhibiting nuclear factors--κB pathway in 3T3-L1 adipocytes[J].J Med Food,2016,19(6):535-542.
[15]OUCHI N,WALSH K.Cardiovascular and metabolic regulation by the adiponectin/C1q/tumor necrosis factor-related protein family of proteins[J].Circulation,2012,125(25):3066-3068.
[16]SHIBATA R,OUCHI N,MUROHARA T.Adiponectin and cardiovascular disease[J].Circ J,2009,73(4):608-614.
(本文編輯:崔麗紅)
Effects of Dietary Pattern Improvement on the Levels of Inflammatory Markers in Middle-aged and Older People with Hypertension in Zhangfang Village of Fangshan District of Beijing
WANGJia,HONGZhong-xin*,WULi,DINGBing-jie,GUZhong-yi,GEZhi-wen,LIULu,BIYan-xia,LIWei
DepartmentofNutrition,BeijingFriendshipHospital,CapitalMedicalUniversity,Beijing100050,China
*Correspondingauthor:HONGZhong-xin,Chiefphysician;E-mail:hongzhongxin@vip.sina.com
Objective To explore the effect of dietary pattern improved by supplementing anti-atherosclerosis therapeutic powder on the levels of inflammatory markers in middle-aged and older people with hypertension in Zhangfang Village of Fangshan District of Beijing.Methods From 27th June to 11th October 2015,we selected 30 overweight or obese patients with grade-1 hypertension meeting the inclusion criteria as the participants of this study from the database of 245 middle-aged and older villagers in Zhangfang Village of Fangshan District of Beijing.We randomized the patients into group 1(n=15) and group 2(n=15).And a cross-over intervention study was conducted on the groups which consisted of 3 stages lasting for 14 weeks.Stage 1(6 weeks):group 2 kept the original dietary pattern but group 1 took anti-atherosclerosis therapeutic powder.Stage 2(2 weeks):group 2 kept the original dietary pattern,but group 1 recovered the original dietary pattern.Stage 3(6 weeks):group 2 took anti-atherosclerosis therapeutic powder,group 1 kept the original dietary pattern.A total of 24 subjects(11 in group 1 and 13 in group 2) completed the trial finally.Before the trial(T0),at the end of the 6th week(T1) and 14th week(T2) of trial,the levels of inflammatory markers including nuclear factor NF-κB,soluble intercellular adhesion molecules-1(sICAM-1),soluble vascular cell adhesion molecule 1(sVCAM-1),endothelium-selectin(E-Selectin),Integrin,Adiponectin,high-sensitivity C-reactive protein(hs-CRP),fasting blood glucose(FBG),fasting insulin(FIN) and homeostatic model assessment of insulin resistance index(HOMA-IR) were measured in the subjects.Results In group 1,sICAM-1 at T1 was higher than that at T2,NF-κB,Integrin at T0 were higher than those at T2(P<0.05).In group 2,sICAM-1 at T1 was higher than that at T2,and sICAM-1,sVCAM-1 at T0 were higher than those at T2(P<0.05).At T0,T1 and T2,there were no significant differences between the two groups in NF-κB,sICAM-1,sVCAM-1,E-Selectin,Integrin,Adiponectin,hs-CRP and HOMA-IR(P>0.05).Conclusion For overweight or obese middle-aged and older hypertension patients,improving the dietary pattern via controlling the total energy intake supplemented by taking anti-atherosclerosis therapeutic powder,can lower the blood pressure to a certain degree by decreasing the levels of inflammation markers long-termly.
Hypertension;Food habits;Inflammation
R 544.1
A
10.3969/j.issn.1007-9572.2017.03.007
2016-12-02;
2016-12-06)
*通信作者:洪忠新,主任醫(yī)師;E-mail:hongzhongxin@vip.sina.com